The risks of pharmacological therapy for insomnia (part 1): Update for the clinical nurse specialist

Clinical Nurse Specialist

Volumn 21, Issue 4, 2007, Pages 188-190

  O'Malley, Patricia ^a  

^a MIAMI VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; HYPNOTIC SEDATIVE AGENT;

CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DRUG APPROVAL; DRUG LABELING; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INSOMNIA; NURSE; NURSE ATTITUDE; NURSING; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SLEEP WALKING; STATISTICS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHRONIC DISEASE; DRUG APPROVAL; DRUG LABELING; DRUG UTILIZATION; HUMANS; HYPNOTICS AND SEDATIVES; NURSE CLINICIANS; NURSE'S ROLE; PATIENT SELECTION; PRACTICE GUIDELINES; PRESCRIPTIONS, DRUG; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, GABA-A; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOMNAMBULISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34447330469     PISSN: 08876274     EISSN: 15389782     Source Type: Journal    
DOI: 10.1097/01.NUR.0000280486.49131.e5     Document Type: Short Survey

References (13)

1. 2003 National Sleep Disorders Research Plan. U.S. Department of Health and Human Services. NIH Publication No. 03-5209. July 2003. Available at: http://www.nhlbi.nih.gov/ about/ncsdr/. Accessed April 30, 2007.
2. National Institutes of Health. NIT State of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. June 13-15, 2005. Available at: http://consensus.nih.gov/2005/2005InsomniaSOS026html. htm. Accessed on April 30, 2007.
3. Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem - sleepwalking: a case report. Arch Phys Med Rehabil. 2005;86:1265-1266.
4. Haraizin J, Berigan TR. Zolpidem tartrate and somnambulism. Mil Med. 1999;164:669-670.
5. Amnesia possibly associated with zolpidem administration. Pharmacotherapy. 1996;16:687-689.
6. Mahoney JE, Webb MJ, Gray SL. Zolpidem prescribing and adverse drug reactions in hospitalized general medicine patients at a Veterans Affairs hospital. Am J Geriatr Pharmacother. 2004;2:66-74.
7. Huang CL, Chang CJ, Hung CF, Lin HY. Zolpidem-induced distortion in visual perception. Ann Pharmacother. 2003;37: 683-686.
8. Goulle JP, Anger JP. Drug facilitated robbery or sexual assault: problems associated with amnesia. Ther Drug Monit. 2004;26:206-210.
9. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system effects associated with zolpidem treatments. Clin Neuropharmacol. 2000;23:54-58.
10. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32:680-691.
11. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18:49-56.
12. FDA Requests Label Change for All Sleep Disorder Drug Products. P07-45. US Food and Drug Administration. March 14, 2007. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html. Accessed April 20, 2007.
13. Mclean B. Valley of the dollars. Fortune. February 14, 2006. Available at: money.cnn.com/magazines/fortune/fortune_archive/2006/02/20/ 8369114/index.htm. Accessed May 4, 2007.